Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT05095779Phase 2Completed
Phase 2, randomised, open-label trial (2 arms), sponsored by University of Oklahoma. Primary endpoint: 7-Day Point Prevalence Abstinence. Started Mar 2022; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT05095779.